- 全部删除
您的购物车当前为空
GPRC5D Protein, Mouse, Recombinant (Flag) is expressed in HEK293 mammalian cells with Flag tag. The predicted molecular weight is 35.8 kDa and the accession number is Q9JIL6-2.

| 规格 | 价格 | 库存 | 数量 |
|---|---|---|---|
| 5 μg | ¥ 1,880 | 6-8日内发货 | |
| 10 μg | ¥ 3,170 | 6-8日内发货 | |
| 20 μg | ¥ 5,330 | 5日内发货 | |
| 50 μg | ¥ 7,730 | 5日内发货 | |
| 100 μg | ¥ 12,200 | 5日内发货 | |
| 200 μg | ¥ 16,800 | 5日内发货 | |
| 500 μg | ¥ 39,200 | 5日内发货 |
| 生物活性 | Recombinant Mouse GPRC5D-VLP (Full Length) Protein (Flag Tag) at 5 μg/mL (100 μL/well) can bind Anti-Human GPRC5D Antibody, Human IgG1, the EC50 is 2.84 ng/mL. |
| 产品描述 | GPRC5D Protein, Mouse, Recombinant (Flag) is expressed in HEK293 mammalian cells with Flag tag. The predicted molecular weight is 35.8 kDa and the accession number is Q9JIL6-2. |
| 种属 | Mouse |
| 表达系统 | HEK293 Cells |
| 标签 | C-Flag |
| 蛋白编号 | Q9JIL6-2 |
| 蛋白构建 | A DNA sequence encoding the Mouse GPRC5D (Q9JIL6-2) (Met1-Cys300) was expressed. Predicted N terminal: Met 1 |
| 分子量 | 35.8 kDa (predicted) |
| 内毒素 | < 1.0 EU/μg of the protein as determined by the LAL method. |
| 蛋白性状 | Solution |
| 缓冲液 | Supplied as sterile 50 mM Hepes, 150 mM NaCl, 10% Trehalose, pH 7.2. |
| 存储 | It is recommended to store the product under sterile conditions at -70°C or lower. Samples are stable for up to 12 months at -80°C. Please avoid multiple freeze-thaw cycles and store products in aliquots. |
| 运输方式 | In general, Lyophilized powders are shipping with blue ice. Solutions are shipping with dry ice. |
| 研究背景 | Orphan G-protein-coupled receptor family C group 5 member D (GPRC5D) has seven transmembrane segments forming the core of the receptor, as well as an intracellular C-tail and an extracellular N-terminal domain. GPRC5D is highly and selectively expressed on the surface of CD138+ multiple myeloma (MM) cells, whereas in normal tissues, a much lower expression is limited to plasma cells and certain hard keratinizing tissues. This makes GPRC5D a promising marker for monitoring tumor load and a target antigen for MM-specific T cell-engaging therapies such as bispecific antibodies and CAR-T cells. |